Medtronic

Q1 FY2027
Speakers

Sep 1, 2026 · 71 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good morning, and welcome to our fiscal 27 First Quarter Earnings webcast. ?I'm Ingrid Goldberg, Head of Medtronic Investor Relations, and I'm joined by Jeff Martha, Chairman and Chief Executive Officer, and Terry Paton, Chief Financial Officer. Jeff and Terry will provide comments on the results of our first quarter, which ended on July 31, 2026, and our outlook for the remainder of the fiscal year 27.

After
our prepared remarks, we'll take questions from the self side analysts that cover the company. Earlier this morning, we issued a press release discussing our quarterly results and several financial schedules. ?We also posted an earnings presentation that provides additional details on our performance. ?The presentation can be accessed in our earnings press release or on our website at investorrelations.medtronic.com. During today's program, many of our statements will be forward-looking, and actual results may differ materially as explained in our SEC filings.

We undertake no obligation to update any forward-looking statements. Unless otherwise
stated, all comparisons are on a year-by-year basis, and revenue comparisons are made on an organic basis, which excludes the impact of foreign currency, first quarter revenue in the current and prior year reported as other, as well as significant acquisitions, to vestitures or other significant distreet items. As a reminder, fiscal 27 is a 53 week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and is included in our Q1 results.

References to sequential revenue changes compared the fourth quarter of fiscal 26 and are made on an as reported basis. Unless otherwise stated, all references to share gains or losses
are on a revenue and year for year 52 week basis, comparing our most recently completed fiscal quarter to our competitors' most recently completed calendar quarter. Reconciliations of all non-gap financial measures can be found in our earnings press release or on our website at investorrelations.medtronic.com.

And finally, our EPS guidance does not include any
charges or gains that would be reported as non-gap adjustments to the earnings during the fiscal year. With that, I'm now pleased to hand it over to you, Jeff.

Passages & reports (12)
  • Good morning, and welcome to our fiscal 27 First Quarter Earnings webcast.
  • I'm
  • Ingrid Goldberg, Head of Medtronic Investor Relations, and I'm joined by Jeff Martha, Chai…
  • our prepared remarks, we'll take questions from the self side analysts that cover the comp…
  • We
  • also posted an earnings presentation that provides additional details on our performance.
  • The
  • presentation can be accessed in our earnings press release or on our website at investorre…
  • stated, all comparisons are on a year-by-year basis, and revenue comparisons are made on a…
  • 53 week fiscal year, with the extra week occurring in the first fiscal month of the first …
  • are on a revenue and year for year 52 week basis, comparing our most recently completed fi…
  • charges or gains that would be reported as non-gap adjustments to the earnings during the …

Speaker 1

Unverified voice label

Okay, thanks, Ingrid, and good morning, everyone. Thank you for joining ?us. Look, Q1 represents a strong start to fiscal 27, with revenue of 9.8 billion and adjusted EPS of $1.45, both well ahead of expectations. Organic revenue growth was 13.7%, reflecting strong underlying market demand and excellent execution across our businesses. Importantly, these results reinforce our confidence in the durability of our growth. Our three largest businesses, CRM, CST, and Surgical, all delivered strong results this quarter.

Cardiac Ablation Solutions
continues to perform exceptionally well, and we are making progress in simplicity, Alta Viva, and robotics with Hugo. And at the same time, our recent acquisitions are contributing to reported growth and strengthening our portfolio for the long term. ?So we are executing, and this quarter's results are a clear proof point. Our strategic and operational focus is translating into stronger commercial performance and greater consistency.

With healthy underlying markets, relentless execution, and multiple growth platforms
all gaining scale, Medtronic is increasingly well positioned to deliver on our fiscal 27 targets and our long term revenue and earnings trajectory. ?So, with that, let's get into the details of what drove the quarter. Starting with cardiac rhythm management, which delivered an outstanding quarter with global growth of 15%. Performance reflected strength across both high power and low power therapies, with contributions from EVICD, Micra, and conduction system pacing, including Omnia Secure.

At more than $5.5 billion in annual revenue, CRM is one of our largest businesses and has been a longstanding source of strength for the company. As an example, Micra, which launched more than a decade
ago, continues to grow at a healthy double-digit rate, which underscores the lasting impact of meaningful innovation within CRM.

Passages & reports (12)
  • Okay, thanks, Ingrid, and good morning, everyone. Thank you for joining
  • us. Look,
  • Q1 represents a strong start to fiscal 27, with revenue of 9.8 billion and adjusted EPS of…
  • excellent execution across our businesses. Importantly, these results reinforce our confid…
  • continues to perform exceptionally well, and we are making progress in simplicity, Alta Vi…
  • So
  • we are executing, and this quarter's results are a clear proof point. Our strategic and op…
  • all gaining scale, Medtronic is increasingly well positioned to deliver on our fiscal 27 t…
  • So,
  • with that, let's get into the details of what drove the quarter. Starting with cardiac rhy…
  • Micra, and conduction system pacing, including Omnia Secure. At more than $5.5 billion in …
  • ago, continues to grow at a healthy double-digit rate, which underscores the lasting impac…

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 1

we're not standing still. We are further advancing innovation across pacing, defibrillation, and diagnostics, supported by a strong pipeline and excellent execution from our teams. Look, CRM is a flagship business for Medtronic, and we continue to view this business as a key source of innovation, one that will drive durable growth for years to

Passages & reports (2)
  • we're not standing still. We are further advancing innovation across pacing, defibrillatio…
  • one that will drive durable growth for years to

Speaker unclear

?come.

Passages & reports (1)
  • come.

Speaker 1

Our ABLE ecosystem continues to resonate with customers as it connects technologies that have traditionally operated in silos. By bringing together AI driven planning, imaging, navigation, robotics, implants, and outcomes data across the surgical journey, ABLE helps surgeons make more informed decisions, operate with greater precision, and learn from each and every case. And our recently launched stealth access platform also meaningfully outperformed this quarter.

While we're still early in the launch, adoption is building,
and customer feedback has been very positive. ?With U.S. spine robotics penetration still in the single digits, we see a significant opportunity to drive ecosystem pull through and extend our leadership position in spine and cranial technologies for years to ?come. Now moving to surgical, which delivered another strong quarter with 9% global growth. Surgical is our largest operating unit with over $6 billion in annual revenue.

Here we're leveraging our decades of innovation and operating room partnerships to build a connected surgical ecosystem. And we're going to dive deeper on this in just a few
minutes. ?In addition to these businesses, our next cycle of large growth opportunities are playing a more significant role in our performance. Cardiac Ablation Solutions delivered another quarter of excellent performance, further strengthening our position in one of the most attractive markets in Medtech.

In Q1, CAS
delivered 88% worldwide growth, reflecting the team's execution and the strength of our platform. Sphere 9 momentum continued with a nine-point increase in US share during the quarter. ?And I'm pleased to share that we achieved an important commitment this quarter, ahead of the timeframe we promised, surpassing the 2 billion mark in trailing 12-month revenue. ?The broader EP space remains healthy, growing in the mid teens, and we continue to expect CAS to grow at more than two and a half times the market rate this fiscal year.

Our U.S. Affair installed base again grew more than 35% sequentially in Q1, demonstrating that we remain in the
early innings of this opportunity. And as we look ahead, our runway extends well beyond today's share gains as we build out a comprehensive EP platform. One that spans mapping, ice catheters, focal ablation software, and single-shot innovation. Positioning ourselves to serve electrophysiologists with a more with more complete solutions and expand the number of patients who can benefit from advanced EP therapies.

This quarter, we expanded our offering with CE Mark for Sphere 9 for the treatment of ventricular arrhythmias, including ventricular tachycardia, opening
the door to a patient population that is notoriously difficult to treat. ?And enrollment in our US VT pivotal trial is also underway. We're only at the beginning for CAS. With a differentiated platform, a growing installed base, expanding indications, and a strong innovation pipeline, we are well positioned to treat more patients, to continue to gain share, and further extend our leadership in this large and growing market.

Now turning to simplicity. Q1 was another strong quarter, and we are increasingly encouraged by this market's evolution. Real-world outcomes, well, they just keep getting better, as evidenced by the three-year data we recently presented.

Passages & reports (21)
  • Our ABLE ecosystem continues to resonate with customers as it connects technologies that h…
  • journey, ABLE helps surgeons make more informed decisions, operate with greater precision,…
  • and customer feedback has been very positive.
  • With
  • U.S. spine robotics penetration still in the single digits, we see a significant opportuni…
  • come. Now
  • moving to surgical, which delivered another strong quarter with 9% global growth. Surgical…
  • minutes.
  • In
  • addition to these businesses, our next cycle of large growth opportunities are playing a m…
  • delivered 88% worldwide growth, reflecting the team's execution and the strength of our pl…
  • And
  • I'm pleased to share that we achieved an important commitment this quarter, ahead of the t…
  • The
  • broader EP space remains healthy, growing in the mid teens, and we continue to expect CAS …
  • early innings of this opportunity. And as we look ahead, our runway extends well beyond to…
  • electrophysiologists with a more with more complete solutions and expand the number of pat…
  • the door to a patient population that is notoriously difficult to treat.
  • And
  • enrollment in our US VT pivotal trial is also underway. We're only at the beginning for CA…
  • further extend our leadership in this large and growing market. Now turning to simplicity.…

And we are pleased to share that the spiral affirmed clinical trial was accepted for a late breaker at TCT this fall. ?Look, the conversations with clinicians is increasingly shifting from awareness to access, and more hospitals are approaching us about establishing RDN programs. Here, our key focus areas are on expanding coverage and integrating RDN into the care pathway. Looking ahead for RDN, our transradial catheter remains on track to launch in the second half of this fiscal year.

This is an important step forward as many interventional cardiology procedures are performed via radial access today, making the therapy easier to integrate into existing workflows and potentially improving patient outcomes. These positive
signals further reinforce our conviction that simplicity is one of the most compelling long-term growth opportunities in MedTech. Now turning to pelvic health. ?The business delivered strong growth this quarter, increasing 15%, driven by significant progress from Alta Viva, where procedures doubled sequentially.

Demand for Alta Viva is building, and while we are still early in our launch, Alta Viva is gaining traction with physicians as well as the
16 million U.S. patients who still suffer from urge urinary incontinence. As we continue to expand training, reimbursement support, and patient awareness, we are really encouraged by the progress we are already seeing. And we are confident in Alta Viva's ability to become a meaningful contributor to growth for years to

Passages & reports (9)
  • And we are pleased to share that the spiral affirmed clinical trial was accepted for a lat…
  • Look,
  • the conversations with clinicians is increasingly shifting from awareness to access, and m…
  • transradial catheter remains on track to launch in the second half of this fiscal year. Th…
  • signals further reinforce our conviction that simplicity is one of the most compelling lon…
  • The
  • business delivered strong growth this quarter, increasing 15%, driven by significant progr…
  • 16 million U.S. patients who still suffer from urge urinary incontinence. As we continue t…
  • meaningful contributor to growth for years to

Speaker unclear

?come.

Passages & reports (1)
  • come.

Speaker 1

Okay, back to surgical. We have a strong leadership position in surgery, built on decades of innovation, trusted technologies, and a long standing partnership with surgeons worldwide. ?As robotic assisted surgery continues to expand, we believe our portfolio breadth, our global reach, and our operating room presence uniquely position us to help shape the future of surgery and extend the benefits of these technologies to more patients around the world.

Robotic assisted surgery, or RAS,
is one of the most compelling growth opportunities in healthcare, with global penetration still in the single digits and only 1% in emerging markets. At the same time, RAS is in high demand, with procedure volumes up approximately 16% per year over the last decade. There is a significant runway here, and we expect robust expansion for many years to come. ?

Now
we've established our foundation in soft tissue robotics with Hugo, where we continue to make meaningful progress. By the end of the fiscal year, we expect Hugo to surpass 50,000 completed procedures, with procedure growth continuing at more than twice the market rate. We're also advancing our platform through new capabilities and new indications, including the expected U.S. expansions into general surgery and gynecology.

We are investing in building out a broader surgical ecosystem, just like in CST, an ecosystem that integrates
robotics, advanced visualization, navigation, instrumentation, and digital technologies, including AI-enabled capabilities like touch surgery. Today, touch surgery is used in more than 1,500 operating rooms globally, supporting AI powered insights, collaboration, and workflows. ?And with touch surgery aid unveiled at SRS, we are bringing 300 times more computing power into the operating room and creating a foundation for increasingly advanced AI capabilities over time.

And now that brings us to cornerstone robotics. As announced this morning, we are further
enhancing and expanding our robotic portfolio through a strategic investment and distribution agreement for Cornerstone's Centir surgical system in select markets outside the U.S. Centir complements Hugo by extending our reach into select international markets and broadening the range of customer needs that we can address as robotic surgery continues to expand globally. ?

So
taken together, the platforms Hugo, Touch Surgery Aid, Centir, and our enhanced surgical instrumentation position Medtronic to build a differentiated global robotics portfolio, combining advanced robotics, AI, visualization, and instrumentation to push the field forward, improving surgical precision and workflow, and serve a broader range of customers and patients around the world.

Passages & reports (17)
  • Okay, back to surgical. We have a strong leadership position in surgery, built on decades …
  • As
  • robotic assisted surgery continues to expand, we believe our portfolio breadth, our global…
  • is one of the most compelling growth opportunities in healthcare, with global penetration …
  • decade. There is a significant runway here, and we expect robust expansion for many years …
  • Now
  • we've established our foundation in soft tissue robotics with Hugo, where we continue to m…
  • advancing our platform through new capabilities and new indications, including the expecte…
  • robotics, advanced visualization, navigation, instrumentation, and digital technologies, i…
  • collaboration, and workflows.
  • And
  • with touch surgery aid unveiled at SRS, we are bringing 300 times more computing power int…
  • enhancing and expanding our robotic portfolio through a strategic investment and distribut…
  • needs that we can address as robotic surgery continues to expand globally.
  • So
  • taken together, the platforms Hugo, Touch Surgery Aid, Centir, and our enhanced surgical i…
  • improving surgical precision and workflow, and serve a broader range of customers and pati…

Look, Q1 performance is further evidence that our strategy is translating into stronger results. We are accelerating growth, advancing innovation, and focusing the portfolio and deploying capital with discipline. Overall, our prog our progress this quarter reinforces our confidence in fiscal 27 and in our long term revenue and earnings growth potential. ?With that, I'm going to turn it over to Tierie to walk through more detailed business results, our financials, and our updated guides.

So over to you, Thierry.

Passages & reports (4)
  • Look, Q1 performance is further evidence that our strategy is translating into stronger re…
  • our progress this quarter reinforces our confidence in fiscal 27 and in our long term reve…
  • With
  • that, I'm going to turn it over to Tierie to walk through more detailed business results, …

Speaker unclear

?Hey,

Passages & reports (1)
  • Hey,

Speaker 2

Unverified voice label

thanks, Jeff, and uh hello everyone. I appreciate you joining today. Before we begin, I'd like to remind everyone that this quarter benefited from the extra selling week, which we estimate contributed approximately $570 million or 670 basis points to total organic enterprise revenue growth. Excluding the impact of the extra week, we delivered our strongest quarterly performance in nearly eight years, excluding COVID comps.

Revenue this quarter was $9.8 billion, up 13.7% on both a reported and organic basis. Geographically, we
saw nearly 16% growth in the US and 12% internationally. Cardiovascular delivered 19% revenue growth this quarter, excluding 25% in the US and 14% internationally. Electrophysiology therapies, or EPT, which includes our CRM and CAS businesses, grew 29%, including 41% in the US and 18% internationally. Within EPT, cardiac ablation solutions was again a significant contributor, delivering 88% growth, up 139% in the US. ?

As
Jeff outlined, while we are gaining share rapidly in CAS, this business is still in the early stages of its trajectory. ?In Q2, we expect to outpace the market by more than 3x, with growth rates moderating over the remainder of the fiscal year as we lap increasingly strong comps. Kardiac rhythm management was up 15% worldwide, including balanced performance between the US and international markets, gaining 80 basis points of global share.

Conduction system pacing continues to gain momentum, adding over 200 basis points to CRM in the first quarter. As CSP adoption expands across a growing patient population, Metronic remains the leader
with CSP-capable leads in both high and low power segments. Our broad portfolio and innovation pipeline position us to extend our leadership in this large franchise. Pivoting to interventional cardiology therapies, which includes structural heart and coronary and renal denovation.

ICT grew 7% globally, driven mainly by 11% international growth. Structural Heart grew low single digits, similarly to Q4. US procedure volume trends remain stable. Our internal programs in mitral and tricuspid
replacement are on track, and we're taking steps to broaden our opportunity over time through targeted external investments, as evidenced by our strategic investment earlier this year in Anteras, ?as well as Pycardia announced this morning.

Pycardia is the first FDA cleared leaflet modification technology for TAVA procedures for patients at risk for coronary obstruction, one of the fastest growing segments in structural heart. Coronary and renal
denovation grew 13% globally. Our coronary business was up low double digits. With CathWorks, our AI and advanced computational science platform for angial based FFR, contributing nearly 300 basis points of organic growth. In Ardian, we continue to make progress in the first quarter.

Positive trends across access, market development, and adoption reinforce our confidence in this very large opportunity. Cardiovascular surgery, which includes our cardiac surgery and aortic businesses, grew 8% globally.
?And peripheral vascular health was up 11%. Now moving to neuroscience. The portfolio grew 9% worldwide, driven by 11% in the US and 7% internationally. Cranial and spinal technologies delivered 13% growth worldwide. Performance was driven by continued strength in core spine up 14%, and neurosurgery up 15%, along with strong contribution from Stealth Access following its first full quarter since commercial launch.

Specialty therapies was up 7%, including 10%
in the US and 4% internationally. Within specialty, neurovascular grew 4% globally, driven by 9% in hemorrhagic and continued strength across flow diversion, intracepular embolization, carotid stenting, and access devices. In August, Onyx 12 received US FDA approval for MMA embolization to treat subdural hematomas. All three ONYX viscosities are now approved for a one-minute shake time versus the conventional 20 minutes.

Passages & reports (22)
  • thanks, Jeff, and uh hello everyone. I appreciate you joining today. Before we begin, I'd …
  • Excluding the impact of the extra week, we delivered our strongest quarterly performance i…
  • saw nearly 16% growth in the US and 12% internationally. Cardiovascular delivered 19% reve…
  • our CRM and CAS businesses, grew 29%, including 41% in the US and 18% internationally. Wit…
  • 139% in the US.
  • As
  • Jeff outlined, while we are gaining share rapidly in CAS, this business is still in the ea…
  • In
  • Q2, we expect to outpace the market by more than 3x, with growth rates moderating over the…
  • international markets, gaining 80 basis points of global share. Conduction system pacing c…
  • with CSP-capable leads in both high and low power segments. Our broad portfolio and innova…
  • and coronary and renal denovation. ICT grew 7% globally, driven mainly by 11% internationa…
  • replacement are on track, and we're taking steps to broaden our opportunity over time thro…
  • as
  • well as Pycardia announced this morning. Pycardia is the first FDA cleared leaflet modific…
  • denovation grew 13% globally. Our coronary business was up low double digits. With CathWor…
  • we continue to make progress in the first quarter. Positive trends across access, market d…
  • And
  • peripheral vascular health was up 11%. Now moving to neuroscience. The portfolio grew 9% w…
  • Performance was driven by continued strength in core spine up 14%, and neurosurgery up 15%…
  • in the US and 4% internationally. Within specialty, neurovascular grew 4% globally, driven…
  • devices. In August, Onyx 12 received US FDA approval for MMA embolization to treat subdura…

This quarter, we completed our acquisition of Scientia, which represents an important advancement in navigation, enabling neurointerventionalists to reach areas of the brain that have historically been extremely difficult to access. Perfect Health delivered 15% growth globally. In SM, Medtronic continues to outpace peers, and Alta Viva's performance is now more than offsetting SM market softness. We're pleased with the continued progress in Alt Viva as physician training expands, reimbursement progresses, and physician experience builds. ?

We
expect pelvic health to become a stronger and stronger contributor to neuroscience in fiscal year 27 and beyond. ENT grew 7% worldwide, driven by low double-digit growth in the US. Neuromodulation was at 3% globally, driven by ongoing SCS market softness and replacement headwinds in DBS. Our neuromodulation position has been strengthened by the acquisition of SPR therapeutics in peripheral nerve stimulation and through our distribution agreement with Merit Medical, which expands our presence in BVNA.

Both segments are growing over 20% annually. Together, these strategic actions increase our exposure to attractive, high-growth markets, and reinforce our broader pain portfolio.

Passages & reports (7)
  • This quarter, we completed our acquisition of Scientia, which represents an important adva…
  • globally. In SM, Medtronic continues to outpace peers, and Alta Viva's performance is now …
  • and physician experience builds.
  • We
  • expect pelvic health to become a stronger and stronger contributor to neuroscience in fisc…
  • driven by ongoing SCS market softness and replacement headwinds in DBS. Our neuromodulatio…
  • BVNA. Both segments are growing over 20% annually. Together, these strategic actions incre…

Speaker unclear

?Now,

Passages & reports (1)
  • Now,

Speaker 2

turning to medical surgical, which had a strong quarter and delivered 10% growth globally, with balanced performance in the US and internationally. Surgical revenue increased 9%, with similar performance across the US and international markets. ?We saw strength in advanced energy and wound management, driven by share gains from our Ligoshore vessel ceiling and VLOC barb sutures. ?As Jeff mentioned, we're pleased with our launch of Hugo, which had an increase in contribution in the quarter.

Endoscopy grew high single digits, driven by further momentum of Endoflip 300 system
?and of PILCAM. Acute care and monitoring was up 14% globally, including high teens growth in the US. Results were driven by mid 40s growth in McGrath video laryngoscopy, high 30s in microstream capnography, and high single digits in NALCOR pulse a symmetry. This performance was a positive tailwind in the quarter.

However, we expect ACM to normalize as we move through 2027. Finally, the diabetes business delivered 15% growth, driven by US acceleration
and robust growth internationally. Our strategic intent for the separation of Minimed is unchanged. Create two focus companies that will allow both Minimed and Metronic to execute more effectively, pursue their distinct capital allocation strategies, and align with the investor basis that best match their respective financial profiles.

Before we shift to the PL and guidance, I wanted to spend a moment on what we're seeing in terms of procedure volumes.

Passages & reports (10)
  • turning to medical surgical, which had a strong quarter and delivered 10% growth globally,…
  • We
  • saw strength in advanced energy and wound management, driven by share gains from our Ligos…
  • As
  • Jeff mentioned, we're pleased with our launch of Hugo, which had an increase in contributi…
  • and
  • of PILCAM. Acute care and monitoring was up 14% globally, including high teens growth in t…
  • single digits in NALCOR pulse a symmetry. This performance was a positive tailwind in the …
  • and robust growth internationally. Our strategic intent for the separation of Minimed is u…
  • investor basis that best match their respective financial profiles. Before we shift to the…

Speaker 2

Importantly, this strength was broad based and not concentrated in any one therapy or region. We continue to see resilient demand across chronic disease, high acuity conditions, and life saving interventions, areas where Medtronic is particularly well positioned given our differentiated innovation and strong clinical evidence. While we continue to monitor the broader environment closely, as usual, the underlying demand backdrop remains constructive and reinforces our confidence in the durability of our growth.

Overall, we're
pleased with Q1 performance as well as the widespread contribution to revenue from many operating units.

Passages & reports (3)
  • Importantly, this strength was broad based and not concentrated in any one therapy or regi…
  • given our differentiated innovation and strong clinical evidence. While we continue to mon…
  • pleased with Q1 performance as well as the widespread contribution to revenue from many op…

Speaker unclear

?Now

Passages & reports (1)
  • Now

Speaker 2

moving down the PL. Our adjusted gross margin was 65.2%, up 10 basis points year over year. ?Now let me walk you through the elements that shape gross margin this quarter. We've maintained our discipline on pricing, which provided 30 basis point benefits, to the quarter. Net of inflation, cost down contributed 50 basis points this quarter, driven primarily by COGS efficiency programs and strong execution across our portfolios, global operations, and supply chain teams.

In Q1, we rationalized more than 9,000 SQUs, further streamlining our product portfolio to focus on the areas with the greatest customer impact, while enhancing supply chain performance and
delivering cost efficiencies across the enterprise. Mix was unfavorable by 50 basis points, largely reflective of the diabetes and caste businesses. Consistent with prior quarters, while the near-term caste capital mix continues to impact our gross margin, it's reflective of our strong commercial performance and growing install base, which is expanding our foundation for future pull-through of higher margin catheter sales over the long term.

The tariff related impact was a slight headwind as tariffs paid were largely
offset by related refunds. And finally, the impact from foreign exchange was roughly neutral. Adjusted SGNA was 32.4% of revenue and increased 14% year over year. We continue to make investments to accelerate the commercialization of our growth opportunities while also integrating several recent acquisitions. Adjusted RD was 7.9% of revenue in Q1 and increased 6% year over year.

Here, we are focused on driving sustainable growth through investment in
innovation, complemented by targeted inorganic opportunities. This discipline is reflected in acquisitions like SPR Therapeutics and Scientia, both of which operate in markets with Kagers exceeding 20%. These businesses are demonstrating strong early traction, and while not reflected in our organic growth today, they're expected to contribute over 150 million to inorganic growth in fiscal year 27.

Our adjusted operating profit was 2.3 billion and increased 15%
year over year. This resulted in an adjusted operating margin of 23.7%, up 10 basis points from the prior year, while we continue to invest behind our highest priority growth opportunities. Our adjusted tax rate was 17.2%, slightly better than expected. The benefit was mostly timing, and we expect this to be offset later in the ?year.

All in, our adjusted EPS was $1.45, six cents above the midpoint of our guidance range, and of street expectations. turning to our guidance. As a reminder, our four-year guidance includes the diabetes business through fiscal year end.
?On the top line, we're pleased with the strong performance in the first quarter and are raising our fiscal year 27 organic revenue growth guidance to 7.25% to 7.75%, which represents a 50 basis points increase from our prior guidance.

In the second quarter,
we're expecting roughly 6% organic revenue growth. Based on recent effects, we expect foreign exchange to be a roughly 50 to 150 million headwind for the full year, with approximate 25 to 75 million headwinds in 2Q. Moving down the PL and starting with gross margin, we continue to expect pricing and cogs efficiency programs to offset the current impact of business mix, which is primarily from diabetes and gas.

This headwind is expected to reduce following the completion of the mini-med separation, which we intend to close
prior to fiscal year end.

Passages & reports (19)
  • moving down the PL. Our adjusted gross margin was 65.2%, up 10 basis points year over year…
  • Now
  • let me walk you through the elements that shape gross margin this quarter. We've maintaine…
  • across our portfolios, global operations, and supply chain teams. In Q1, we rationalized m…
  • delivering cost efficiencies across the enterprise. Mix was unfavorable by 50 basis points…
  • reflective of our strong commercial performance and growing install base, which is expandi…
  • offset by related refunds. And finally, the impact from foreign exchange was roughly neutr…
  • commercialization of our growth opportunities while also integrating several recent acquis…
  • innovation, complemented by targeted inorganic opportunities. This discipline is reflected…
  • strong early traction, and while not reflected in our organic growth today, they're expect…
  • year over year. This resulted in an adjusted operating margin of 23.7%, up 10 basis points…
  • better than expected. The benefit was mostly timing, and we expect this to be offset later…
  • year.
  • All in, our adjusted EPS was $1.45, six cents above the midpoint of our guidance range, an…
  • On
  • the top line, we're pleased with the strong performance in the first quarter and are raisi…
  • we're expecting roughly 6% organic revenue growth. Based on recent effects, we expect fore…
  • starting with gross margin, we continue to expect pricing and cogs efficiency programs to …
  • prior to fiscal year end.

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 2

continue to make targeted investments that are focused on our highest priority growth opportunities and are intended to strengthen the durability of our long-term revenue profile. Taken together, we expect fiscal year 27 operating profit ?to grow approximately 10% with operating margin expanding approximately 50 basis points year over year. Moving to EPS, given the strength in the first quarter, we're also raising our fiscal 27 guidance range to $5.94 to $6.

For the
second quarter, we expect EPS in the range of $1.32 to $1.34, which includes a roughly neutral impact from foreign exchange at recent rates. To close, we are well positioned for a strong year. I'm encouraged by the strength of our first quarter performance and the continued progress we made against our strategic priorities. At the same time, our operational focus has begun translating into our financial results.

Portfolio simplification, SKU rationalization, cost out, and broader
supply chain initiatives are beginning to deliver structural efficiencies down the PL, and we see further opportunity ahead. We're pairing that discipline with targeted organic and inorganic investment to accelerate innovation and support commercialization and expand our growth platforms. Look, we are laser focused ?on translating stronger growth and enhanced efficiency into durable earnings leverage. With that, back to you, Jeff.

Passages & reports (9)
  • continue to make targeted investments that are focused on our highest priority growth oppo…
  • to
  • grow approximately 10% with operating margin expanding approximately 50 basis points year …
  • second quarter, we expect EPS in the range of $1.32 to $1.34, which includes a roughly neu…
  • performance and the continued progress we made against our strategic priorities. At the sa…
  • supply chain initiatives are beginning to deliver structural efficiencies down the PL, and…
  • expand our growth platforms. Look, we are laser focused
  • on
  • translating stronger growth and enhanced efficiency into durable earnings leverage. With t…

Speaker 1

Okay, thanks, Terry. Q1 was a strong start to fiscal 27, and another proof point that our strategy is translating into results. What gives us confidence is not simply the strength of the quarter, but also the breadth of our performance this quarter. Growth is being driven by several businesses, multiple innovation platforms, and teams who are executing at a high level across Medtronic.

Passages & reports (2)
  • Okay, thanks, Terry. Q1 was a strong start to fiscal 27, and another proof point that our …
  • several businesses, multiple innovation platforms, and teams who are executing at a high l…

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 1

look forward to sharing a deeper look at our portfolio and our pipeline and our capital allocation strategy, as well as our long-term growth opportunities at our upcoming investor day, scheduled for December 10th and 11th. With that, I'd like to thank our Medtronic colleagues around the world. The progress we are making reflects the discipline, focus, and execution of our teams. I want to thank you for your hard work and continued commitment to reaching more patients.

Together, we bring our mission to life for the people who are counting on us the most. Okay, let's turn to QA now. And Ingrid,
please provide the instructions and cue up the analysts.

Passages & reports (3)
  • look forward to sharing a deeper look at our portfolio and our pipeline and our capital al…
  • discipline, focus, and execution of our teams. I want to thank you for your hard work and …
  • please provide the instructions and cue up the analysts.

Speaker unclear

?For

Passages & reports (1)
  • For

Speaker 0

the cell side analysts that would like to ask a question, please select the participants button and click Raise Hand. ?If you're using the mobile app, press the More button and select Raise Hand. Your lines are currently on mute, and when called upon, you'll receive a request to unmute your line, which you must respond to before asking your question. Finally, please be advised that the QA session is being recorded.

We'll now pause for
a few seconds to assemble the queue.

Passages & reports (4)
  • the cell side analysts that would like to ask a question, please select the participants b…
  • If
  • you're using the mobile app, press the More button and select Raise Hand. Your lines are c…
  • a few seconds to assemble the queue.

Questions & answers

Speaker 0

Our first question comes from Travis Steed at Bank of America. Go ahead, Travis.

Passages & reports (1)
  • Our first question comes from Travis Steed at Bank of America. Go ahead, Travis.

Speaker 3

Unverified voice label

Hey everybody, congrats on a great quarter. Um, I guess I want to s CAS is doing really well, but I want to spend a second on kind of the Medtronic business XCAS and just kind of the ability to accelerate and improve kind of the base business X CAS at Medtronic kind of going forward. We saw Alta Viva having an impact. So maybe to spend some time on that.

And then and then also the investments this morning with the Cornerstone deal. When when does that show up in kind of the base surgery revenue? And how does that that contract structured with with Cornerstone? And then Terry
wanted to also follow up the margin guide. I think ticked down like 10 basis points from 50 basis points from 60 to 50 basis points.

Just wanted to clarify that if that's because of the some of the investments you you've done this this year.

Passages & reports (3)
  • Hey everybody, congrats on a great quarter. Um, I guess I want to s CAS is doing really we…
  • forward. We saw Alta Viva having an impact. So maybe to spend some time on that. And then …
  • wanted to also follow up the margin guide. I think ticked down like 10 basis points from 5…

Speaker 1

Okay. Uh a couple of their questions there. Thanks for the questions, Travis. Uh, you know, first on the I'll take I'll start on the first one, just on on the business performance and and get it XCAST. I say, first of all, ?the what we like about the quarter is the breadth and the depth of the of the performance, right? You had um you know uh a number of businesses are including our big three perform really well.

Um do you uh Cardiac rhythm, CST, and improving performance in surgical. And on that breadth note, you know,
a lot of different countries around the world contributed to the growth. And then as you point out, you know, we had a number of growth drivers on top of this to give you the depth, right? The CASP being the biggest one, but also some good progress, you know, in Alta Viva, you know, Ardean, Hugo.

So we've got these growth drivers all moving forward. So look from our perspective, the performance was broad based, and we had strong execution. And it's really, as we we talked about this last quarter, the compounding impact of a lot of strategic uh operational and cultural changes that we've made.
?So, beyond CAS, like you said, you're getting to your question. Like I said, we have these other growth drivers that we're feeling really good about.

You know, we can talk about the announcement we made this morning in in Instructural Heart with Picardia, as well as in soft tissue robotics with with send with um
uh cornerstone robotics. Uh there's a lot to talk about and RD and is making is making good progress as well. And Alta Viva is starting to inflect. So and and on top of that you've got um you know stealth access uh you know really doing well in in CST.

So we feel good
about these other growth drivers but if I go around the horn I mean just talk about neuroscience for a second. Lots going on there. I mentioned stealth access in CST. We talked about Alta Viva. We can get more into that. And then in neurovascular we see our you know an acceleration here in the back half of the year getting that business to mid single digit.

You know, it's partly you know the the acquisition of cyanilla, that's not in our uh in our organic growth. And and on top of that, we'll get to this mid single digit, but it is it it is getting us into
more cases, and we've got a lot of new products there, more indications for onyx. You know, we've got uh carotid stenting uh and and we've got RT.

So we've got a number of new products there that are driving then, of course, in in pain stim in our neuromod business. We got the new
BVNA partnership that's it's accelerating, uh, as well as uh SPR, which is moving us upstream. And so that business will will benefit from that. So you're gonna see a nice acceleration uh in neuroscience, uh continued performance in in cardiovascular, and you're seeing the acceleration in in surgery.

Uh I don't know,
Tyr, if you want to add to that and get to the guy question.

Passages & reports (13)
  • Okay. Uh a couple of their questions there. Thanks for the questions, Travis. Uh, you know…
  • the
  • what we like about the quarter is the breadth and the depth of the of the performance, rig…
  • a lot of different countries around the world contributed to the growth. And then as you p…
  • Ardean, Hugo. So we've got these growth drivers all moving forward. So look from our persp…
  • So,
  • beyond CAS, like you said, you're getting to your question. Like I said, we have these oth…
  • uh cornerstone robotics. Uh there's a lot to talk about and RD and is making is making goo…
  • about these other growth drivers but if I go around the horn I mean just talk about neuros…
  • the back half of the year getting that business to mid single digit. You know, it's partly…
  • more cases, and we've got a lot of new products there, more indications for onyx. You know…
  • BVNA partnership that's it's accelerating, uh, as well as uh SPR, which is moving us upstr…
  • Tyr, if you want to add to that and get to the guy question.

Speaker 2

I would say you know, one one thing that I I mentioned, you mentioned the different investments that we made uh in aggregate, you know, we're we should expect uh around 150 million worth of revenue in the in the full year from these acquisitions with a you know kind of a partial year impact. And it's it's in organic for now, but it will turn into or inorganic for now, it will turn into organic.

And all of these investments and acquisitions are in in areas where the Kager is significantly higher than the rest of the business, right? We're talking uh segments where where the growth is typically
north of 20%. So that's further good news down the road. I think one that that uh I would mention um you you talked about neuroscience. In neuroscience, in every single segment, we have meaningful innovation happening.

So we have stealth access in CST, you talked about Scientia, Onyx, NeuroGuard,
Artis in in neurovascular, uh, we've got Stealth Access ENT version for the ENT business, an Apex Cut that's coming out. So every franchise there has good news going forward. So look, uh, I I think we've got uh a lot of good news uh ahead of us. And there was a question on Cornerstone, but maybe to talk about the the margin question, uh Travis.

Um there's uh yeah, it's it's really the result of uh of the investments that we're making. So just to talk about the guidance for a moment, uh so we're raising the revenue guidance by 50 basis points and slightly raising the EPS. The
way to think about the EPS raise is um, you know, we we took uh we took the upside of the first quarter, and then a couple things, I would say part of it, about a cent is driven by tax, which is timing, which we assume is going to come back the other way for the rest of the year.

We've embedded now in the guidance the foregone interest that is going to come from the investment that we just made in Cornerstone. So it's it's a 700 million investment, and we're going to have some foregone interest on that. And then to your point, what we're doing is
we're taking a portion of the upside from a revenue perspective and a portion only and reinvesting that to accelerate our commercial performance.

The last thing I would say is this is only the first quarter, right? And we want to set the business up for success in the remainder of the year.

Passages & reports (8)
  • I would say you know, one one thing that I I mentioned, you mentioned the different invest…
  • And it's it's in organic for now, but it will turn into or inorganic for now, it will turn…
  • north of 20%. So that's further good news down the road. I think one that that uh I would …
  • Artis in in neurovascular, uh, we've got Stealth Access ENT version for the ENT business, …
  • but maybe to talk about the the margin question, uh Travis. Um there's uh yeah, it's it's …
  • way to think about the EPS raise is um, you know, we we took uh we took the upside of the …
  • for the rest of the year. We've embedded now in the guidance the foregone interest that is…
  • we're taking a portion of the upside from a revenue perspective and a portion only and rei…

Speaker 1

I'm sure we're going to get more questions on Cornerstone and Picardia, but just high level, ?you know, I'd say, you know, first on Picardia, uh, excited about the investment. And it's part of a broader theme in Structural Heart where we're just making doubling down on that space. You know, uh we made the Interis investment um a few a few months ago uh in the in the Tabor space.

Uh you
know, we're we're investing heavily in in tricuspid and and and mitral. Um we've got uh an ecosystem that we're building with DASI on the sizing as well, and now Picardia here is just another investment in the space, uh and we're we're bullish on it and we're gonna keep going there. Um and in terms of uh cornerstone, look, it we're just really excited about our progress in soft tissue.

We've made a lot of progress. We talked about it in the commentary on Hugo. That's our play in the US. Cornerstone is really about access and choice. It's a global play for us. It's one of a number
of investments we're making in soft tissue. But this one in particular, it's a global play. It gives customers choice around the world, and we're really excited about it.

And it just goes with a bunch of other investments we're making. We, you know, our touch surgery uh platform, our digital platform, we believe we're
leading and we've got a nice lead in touch surgery. And we were at 1500 installed base. We just rolled out our newest version of that aid, which is like 300 times more computing power in the surgical suite.

We're investments in visualization, you know, robotic instrumentation. So there's a lot going on in soft
tissue, and we're really excited about our progress

Passages & reports (8)
  • I'm sure we're going to get more questions on Cornerstone and Picardia, but just high leve…
  • you know,
  • I'd say, you know, first on Picardia, uh, excited about the investment. And it's part of a…
  • know, we're we're investing heavily in in tricuspid and and and mitral. Um we've got uh an…
  • terms of uh cornerstone, look, it we're just really excited about our progress in soft tis…
  • of investments we're making in soft tissue. But this one in particular, it's a global play…
  • leading and we've got a nice lead in touch surgery. And we were at 1500 installed base. We…
  • tissue, and we're really excited about our progress

Speaker unclear

?there.

Passages & reports (1)
  • there.

Speaker 3

Great. Thanks a

Passages & reports (1)
  • Great. Thanks a

Speaker unclear

?lot.

Passages & reports (1)
  • lot.

Speaker 0

All right, great. Thanks, Travis. Our next question comes from Larry Beagleson at Wells Fargo. ?Go ahead, Larry.

Passages & reports (3)
  • All right, great. Thanks, Travis. Our next question comes from Larry Beagleson at Wells Fa…
  • Go
  • ahead, Larry.

Speaker 4

Unverified voice label

Good morning. Thanks for taking the question. I'll keep it at one, Jeff, and ?you know, follow up on Cornerstone. Just maybe, ?you know, expand on the deal rationale. I'm gonna just ask it head on. Some investors may think this is a signal you're not confident in you go, you know, address that and maybe a little bit more on the financial implications and ?and you know which markets um you're gonna launch this in and whether it includes uh, you know, the US.

And just lastly, is there an option to acquire the company? Thanks for taking the question.

Passages & reports (7)
  • Good morning. Thanks for taking the question. I'll keep it at one, Jeff, and
  • you
  • know, follow up on Cornerstone. Just maybe,
  • you
  • know, expand on the deal rationale. I'm gonna just ask it head on. Some investors may thin…
  • and
  • you know which markets um you're gonna launch this in and whether it includes uh, you know…

Speaker unclear

?Well,

Passages & reports (1)
  • Well,

Speaker 1

look, we've got uh Mike Marinero on the line here, too, from uh our medical surgical portfolio. I'm gonna turn it to him for a second, and then maybe Thierry can hit some of the financial questions. But on the on the Hugo question, it's it's just the opposite. I mean, we're very excited about the progress that we're making in Hugo. We talked about it in the commentary. ?

You
know, we'll be by the end of the fiscal year over 50,000 cases, you know, um 250 units installed. You know, we're we're continuing to roll out new, we're getting new and clinical indications. We expect multiple new indications by in the fall here. We're investing. I was just in our North Haven Connected facility where we do a lot of the instrumentation last week, and we've got a host of new instruments coming out.

So we're we're really bullish about Hugo. You know, that that that is our US play and and and other countries as well. But you know, Cornerstone, like I said, does give us, you know,
it's a like a more of a global play, um, gives our customers it it helps us drive up access to robotic surgery, which is very underpenetrated, particularly in emerging markets.

Uh and and it gives our customers choice. And and maybe I'll call on Mike to provide a little bit more uh detail and
answer some of the other questions, and we'll go back to Terry on the financial side.

Passages & reports (7)
  • look, we've got uh Mike Marinero on the line here, too, from uh our medical surgical portf…
  • the progress that we're making in Hugo. We talked about it in the commentary.
  • You
  • know, we'll be by the end of the fiscal year over 50,000 cases, you know, um 250 units ins…
  • where we do a lot of the instrumentation last week, and we've got a host of new instrument…
  • it's a like a more of a global play, um, gives our customers it it helps us drive up acces…
  • answer some of the other questions, and we'll go back to Terry on the financial side.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 5

Unverified voice label

thanks, Jeff. And uh and Larry, thanks for the question. I think Jeff covered ?it you know very well. This is a this is a uh uh distribution uh and partnership deal that we're very excited ?about. As Jeff mentioned, this is a global play. It's an opportunity for us to build out a full portfolio of robotics, a full portfolio offering and an ecosystem.

And it builds on the progress that we've made with Hugo. I think Jeff just spoke to it, but
?you know, this quarter we've spoken about now our expectations around installs. Really pleased to see with Hugo that our procedure volume continues to grow at two times the market rate. And then our digital ecosystem, of course, is now expanding. ?I think as you've seen at Society of Robotic Surgery, I know you have a prominent presence there.

Uh, there is a you know growing suite of capabilities globally. And it's becoming clear to us that
?you know there are going to be you know two or three platforms that will win in the market. And this is an opportunity for us to build out a portfolio of offerings that really meets the customer need uh and and the specifics of the customer situation you know very well where they sit.

And so this is a
?you know an opportunity for us to take that strategy and expand access in one of the largest markets in MedTech that is still highly underpenetrated. And we see it as complementary and uh and really just an expression of our confidence in the progress that that we continue to make uh make here with Hugo. ?You know, lastly I'd say, you ?know, we're in this to win.

You know, this is uh a critical area for us. You know, we are leaders in surgery and this investment is an investment to build out that portfolio of offerings because we're here to win and we're excited about you know this this platform and portfolio that you know that
we'll build uh together between Hugo Cornerstone and our touch surgery ecosystem

Passages & reports (20)
  • thanks, Jeff. And uh and Larry, thanks for the question. I think Jeff covered
  • it you
  • know very well. This is a this is a uh uh distribution uh and partnership deal that we're …
  • about.
  • As Jeff mentioned, this is a global play. It's an opportunity for us to build out a full p…
  • you
  • know, this quarter we've spoken about now our expectations around installs. Really pleased…
  • I
  • think as you've seen at Society of Robotic Surgery, I know you have a prominent presence t…
  • you
  • know there are going to be you know two or three platforms that will win in the market. An…
  • And so this is a
  • you
  • know an opportunity for us to take that strategy and expand access in one of the largest m…
  • Hugo.
  • You
  • know, lastly I'd say, you
  • know,
  • we're in this to win. You know, this is uh a critical area for us. You know, we are leader…
  • we'll build uh together between Hugo Cornerstone and our touch surgery ecosystem

Speaker unclear

?and

Passages & reports (1)
  • and

Speaker 2

then on on the financials uh hi Larry. Um, just so for this year, other than the uh impact of the foregone interest that I mentioned in the previous question, uh, the impact should be minimal. ?Uh starting in 28, though, we should start seeing the impact of the distribution agreement. ?Um, and and this will contribute to the growth, the growth that we're experiencing coming from robotics, generally speaking, first with Hugo and now with uh Centaire, ?uh, making that stronger and stronger.

So we we do expect to see a lift in volume and in margins coming into 28 through the distribution agreement. The question on the acquisition look, we on the potential acquisition, we we just made a large, a large investment. The investment that we made does provide us some
strategic optionality going forward, I would say. But the way we're approaching it is uh similar to what we do in a lot of these investments.

We like to take a position, have a seat on the board, understand how the company is being run, start developing the collaboration. And then once we understand we
understand what's under the hood, so to speak, consider our options. So some optionality there.

Passages & reports (9)
  • then on on the financials uh hi Larry. Um, just so for this year, other than the uh impact…
  • Uh
  • starting in 28, though, we should start seeing the impact of the distribution agreement.
  • Um,
  • and and this will contribute to the growth, the growth that we're experiencing coming from…
  • uh,
  • making that stronger and stronger. So we we do expect to see a lift in volume and in margi…
  • strategic optionality going forward, I would say. But the way we're approaching it is uh s…
  • understand what's under the hood, so to speak, consider our options. So some optionality t…

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 1

you know, just Larry, just to re-emphasize, I just want to make sure we're not mincing any words here and there's no earnings speak. We are doubling down here. We have a lot of confidence and conviction about our position in soft tissue right now. And as Mike said, that's the key. We're in it, we're building a winning strategy here. We we feel good about our position, feel good about Hugo.

We've got confidence and conviction, but there's no arrogance, as my college hockey coach used to say, head on a swivel, panther-like stance. There's there's lots going on here, and and we've got to continue to invest and
can and continue to uh to execute here. We like, you know, our our we want to become that meaningful number two and gain on the market leader, and we really like the what we believe is a multi-year, you know, head start over the next uh scaled competitor, which is important.

Passages & reports (3)
  • you know, just Larry, just to re-emphasize, I just want to make sure we're not mincing any…
  • we're building a winning strategy here. We we feel good about our position, feel good abou…
  • can and continue to uh to execute here. We like, you know, our our we want to become that …

Speaker 4

Thank you very much.

Passages & reports (1)
  • Thank you very much.

Speaker 0

Thanks, everyone. ?So Vijay Kumar, you are next. Vijay at Evercore. Please go ahead.

Passages & reports (3)
  • Thanks, everyone.
  • So
  • Vijay Kumar, you are next. Vijay at Evercore. Please go ahead.

Speaker 4

Hi, Jeff.

Passages & reports (1)
  • Hi, Jeff.

Speaker 6

Unverified voice label

Thank you for taking my question. Congrats on a nice sprint this morning. I had a two-parter for you, Jeff. One on diabetes split-off timing. When you look at Mitronic versus stock prices and minimum stock, obviously it's it's come off the bottom. You know, why why not? Um, you know, what is the hesitancy in in uh announcing the split off in one on that cas. ?

I
want to make sure I heard this correctly. I think your prior comment was ?you know, grow about twice the rate of market growth. And I think uh today you've said two and a half uh X the uh rate of market growth. So did underlying cash assumptions improve and uh what is driving this uh uh confidence? Thank you.

Passages & reports (6)
  • Thank you for taking my question. Congrats on a nice sprint this morning. I had a two-part…
  • in in uh announcing the split off in one on that cas.
  • I
  • want to make sure I heard this correctly. I think your prior comment was
  • you know,
  • grow about twice the rate of market growth. And I think uh today you've said two and a hal…

Speaker unclear

?Well,

Passages & reports (1)
  • Well,

Speaker 1

thanks, VJ, for the question. I maybe I'll start with the cas question and then Thierry can take the the diabetes question. Yeah, we did say for the balance of the fiscal year that uh we would grow uh two and a half times the market. And we think the market's mid teens uh and in in in Q3 or Q2 rather, it might even be higher than that.

Uh so look, we're just there's a lot going on in CAS. I'd say, you know, there's first of all, there's still room to run on Sphere 9, right? We're, you know, still relatively early in that in that launch, as
evidenced by the the the 35% uh sequential growth over the prior quarter. It tells you we're still early. Um, you know, and Sphere 9 remains kind of one of a kind in that dual energy point-to-point space.

And it's just with a lot of different features and benefits that physicians
like, and it continues to grow. And we're getting more clinical indications there. We're on the, you know, we took out a C mark for VT, you know, we're geographic expansion. We're just launching in Japan. So it's just a lot of room to run on that ?one. And then we're, you know, we're starting to see progress at Sphere 360 in Europe.

And we're going to keep keep going here. We're building out an ecosystem. That's a trend here at Medtronic. You saw it in CST, this procedural or surgical ecosystem. We're doing that in soft tissue, and we're now doing it
in various areas of cardiology, Casping One. We talked about two investments in ICE technology last quarter. And we're going to keep going. So again, not too dissimilar from soft tissue.

I mean, uh, we like our position. Uh on this one, you know, we're further ahead uh and and it and marching towards that
market leadership, but you gotta keep investing here, not just in the in the therapy itself, uh, but also the ecosystem around it. And I forgot about mapping too, the integrated mapping, you know, continued to kind of drive mapping upgrades every year.

So there's a lot going on in in CAS, and that's driving
our plus you got a great in you know uh market, right? Uh the market is is growing you know fast. So all that is giving us the confidence and conviction. ?And then I'll turn over you on diabetes.

Passages & reports (11)
  • thanks, VJ, for the question. I maybe I'll start with the cas question and then Thierry ca…
  • in in in Q3 or Q2 rather, it might even be higher than that. Uh so look, we're just there'…
  • evidenced by the the the 35% uh sequential growth over the prior quarter. It tells you we'…
  • like, and it continues to grow. And we're getting more clinical indications there. We're o…
  • one.
  • And then we're, you know, we're starting to see progress at Sphere 360 in Europe. And we'r…
  • in various areas of cardiology, Casping One. We talked about two investments in ICE techno…
  • market leadership, but you gotta keep investing here, not just in the in the therapy itsel…
  • our plus you got a great in you know uh market, right? Uh the market is is growing you kno…
  • And
  • then I'll turn over you on diabetes.

Speaker 2

Yeah, and on just on CAS, it's you're you're right, Vijay, it's two and a half times the uh the market on the four year. We we expect it to be north of three times the market in the second quarter. So expect uh another good quarter in Q2 despite comps that are getting tougher and tougher. Uh on diabetes, look uh first uh uh as as you mentioned, it's great to see that the stock is has come come back up, um, and we're encouraged to see that.

I think it's it's uh a testament to the fact that the business is performing, right? So so they had a
good fourth uh fourth quarter last year. Uh as you can see in the print here, and Chad and Q will give you more details a bit later. They had a good first quarter, so growth is accelerating, in particular in the US. They have a ton of favorability from an innovation perspective.

Every single
launch is happening ahead of schedule, which is great news. So it's super encouraging going forward. There's no hesitation on our side, so no change in schedule or anything like that. We had mentioned that we would do the separation when we think the economics are optimal for our shareholders and for our stakeholders, generally speaking. And we stick to that position. So no no hesitating, no hesitation going forward with the separation, just when the time is

Passages & reports (5)
  • Yeah, and on just on CAS, it's you're you're right, Vijay, it's two and a half times the u…
  • and tougher. Uh on diabetes, look uh first uh uh as as you mentioned, it's great to see th…
  • good fourth uh fourth quarter last year. Uh as you can see in the print here, and Chad and…
  • launch is happening ahead of schedule, which is great news. So it's super encouraging goin…
  • speaking. And we stick to that position. So no no hesitating, no hesitation going forward …

Speaker unclear

?right.

Passages & reports (1)
  • right.

Speaker 6

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you. All

Passages & reports (1)
  • you. All

Speaker 0

right, great. Next question comes from Mike Cracky at Learink. Mike, go ahead.

Passages & reports (1)
  • right, great. Next question comes from Mike Cracky at Learink. Mike, go ahead.

Speaker 7

Unverified voice label

Awesome. Can you hear me all right?

Passages & reports (1)
  • Awesome. Can you hear me all right?

Speaker 1

Yep.

Passages & reports (1)
  • Yep.

Speaker 2

Yep.

Passages & reports (1)
  • Yep.

Speaker 7

Great. So uh congrats on the strong quarter. Thanks very much for taking our question. ?You know, really encouraging to see the 35% sequential growth for your US affair install base, you know, after 40% last quarter. So can you provide any additional color on utilization trends in centers after they've added an affair system? How quickly are you seeing your PFA market share shift in those centers?

And where are
you seeing your share kind of stabilize over time there?

Passages & reports (4)
  • Great. So uh congrats on the strong quarter. Thanks very much for taking our question.
  • You
  • know, really encouraging to see the 35% sequential growth for your US affair install base,…
  • you seeing your share kind of stabilize over time there?

Speaker 1

Well, we're seeing um ?let me see here. I I'll go on my notes here. Uh ?well, so first of all, 75% of our US installed base are at at high volume centers, right? So right now we're still concentrated in these high volume centers, which is not a bad thing. But it also tells us we get we got room to ?run in the lower volume centers across across the U.S.

30% of our accounts are are doing 70% of the ablations, right? These are high volume centers. That's the 300-plus ablations a year. That's what we define as a high volume center. Um and then you know, many of these large accounts have only one or
two systems and they're and they're asking for more. So we're seeing like once the Affair goes in there, we most of our experience, Mike, is in these high volume accounts, ?right?

And and once our system gets in there, the utilization is high. We're seeing them, you know, you know, add systems. Uh and and so we're we're that's all good to sign. That utilization number is something we're watching every quarter. And like I said, so we're focused on those high volume centers, and we've
got a lot of room to ?run in centers outside of these high volume centers. ?

Do you have
anything to add there?

Passages & reports (15)
  • Well, we're seeing um
  • let
  • me see here. I I'll go on my notes here. Uh
  • well,
  • so first of all, 75% of our US installed base are at at high volume centers, right? So rig…
  • run
  • in the lower volume centers across across the U.S. 30% of our accounts are are doing 70% o…
  • two systems and they're and they're asking for more. So we're seeing like once the Affair …
  • right?
  • And and once our system gets in there, the utilization is high. We're seeing them, you kno…
  • got a lot of room to
  • run
  • in centers outside of these high volume centers.
  • Do you have
  • anything to add there?

Speaker 2

No, I think I think I'm glad you picked up on the 35%, because it's 35% in Q1 after 40% in Q4. So if you think of just the mathematical mechanical impact of what that means from a pull-through perspective, it's just super encouraging.

Passages & reports (1)
  • No, I think I think I'm glad you picked up on the 35%, because it's 35% in Q1 after 40% in…

Speaker 1

And for just a variety of reasons, I won't go through all the list of benefits. It's ?you know, FAIR is becoming the workhorse uh in in these centers, uh, and that bodes well. And then we've got few 360 coming, uh, which which, like, as I mentioned earlier, goes right at the heart of the largest, our largest PFA competitor. So feeling feeling you know bullish on on CAS right

Passages & reports (3)
  • And for just a variety of reasons, I won't go through all the list of benefits. It's
  • you
  • know, FAIR is becoming the workhorse uh in in these centers, uh, and that bodes well. And …

Speaker unclear

?now.

Passages & reports (1)
  • now.

Speaker 7

Understood. Thanks very

Passages & reports (1)
  • Understood. Thanks very

Speaker unclear

?much. All

Passages & reports (1)
  • much. All

Speaker 0

right, great. Next question comes from Anthony Patron at Mizuho. Please go ahead, Anthony.

Passages & reports (1)
  • right, great. Next question comes from Anthony Patron at Mizuho. Please go ahead, Anthony.

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 7

thanks ?and uh congratulations here on a solid quarter. ?I'll I'll stick to one and maybe ?you know

Passages & reports (7)
  • thanks
  • and uh
  • congratulations here on a solid quarter.
  • I'll
  • I'll stick to one and maybe
  • you
  • know

Speaker 5

go back to VJ, which is maybe capital allocation and diabetes, ?it will be a pretty significant hole in a portfolio. It's

Passages & reports (3)
  • go back to VJ, which is maybe capital allocation and diabetes,
  • it
  • will be a pretty significant hole in a portfolio. It's

Speaker 6

also growth

Passages & reports (1)
  • also growth

Speaker 5

accretive based on the quarterly numbers for this fiscal quarter, diabetes ?growing 15, excluding ?the week, you're at

Passages & reports (5)
  • accretive based on the quarterly numbers for this fiscal quarter, diabetes
  • growing
  • 15, excluding
  • the week, you're
  • at

Speaker unclear

?roughly 7%. So maybe how the capital

Passages & reports (1)
  • roughly 7%. So maybe how the capital

Speaker 6

allocation

Passages & reports (1)
  • allocation

Speaker unclear

?will change post-diabetes, uh being completely separated. Will the cadence of tuck-in deals accelerate?

Passages & reports (1)
  • will change post-diabetes, uh being completely separated. Will the cadence of tuck-in deal…

Speaker 7

Will you consider scale deals? Is a buyback, you know, you know, in in in in the cards here as

Passages & reports (1)
  • Will you consider scale deals? Is a buyback, you know, you know, in in in in the cards her…

Speaker 5

well, considering that med tech valuations are are off the bottom but are still you

Passages & reports (1)
  • well, considering that med tech valuations are are off the bottom but are still you

Speaker 6

know

Passages & reports (1)
  • know

Speaker 5

certainly not at multi-year

Passages & reports (1)
  • certainly not at multi-year

Speaker 6

highs.

Passages & reports (1)
  • highs.

Speaker unclear

?So just

Passages & reports (1)
  • So just

Speaker 5

looking ?ahead to what the capital allocation

Passages & reports (3)
  • looking
  • ahead to what the
  • capital allocation

Speaker unclear

?uh program

Passages & reports (1)
  • uh program

Speaker 6

looks like

Passages & reports (1)
  • looks like

Speaker unclear

?post uh diabetes. Thanks again. Well

Passages & reports (1)
  • post uh diabetes. Thanks again. Well

Speaker 1

thanks Anthony for the question. I mean I I Terry can comment on the on the uh financial impact here but but on the growth side, ?you know at the Medtronic level it it it's about 20 basis points, right? It's not, ?you know, and with our growth accelerating, uh, you know, we're very comfortable. And as we know, as we you know project forward, we're comfortable with losing that 20 basis points.

And it's and from a profitability standpoint, from a gross margin standpoint, it's a big step up. Terry can walk walk through that.
?You know, look, the the diabetes business is it is fundamentally different from the rest of Medtronic. That's why we made this decision. Uh it's more consumer-based. There's a number of other reasons, but financially, also that industry is a lower margin business, right, on its best day, material lower than the rest of Medtronic.

And so
getting that capital allocation question, ?you know, I wouldn't say anything's changed. We've already made that switch, and you're seeing it in our performance. We've made that switch to allocating our capital to the highest growth opportunities in MedTech, the highest growth, but also where you have confidence that they're going to be big. So high growth, large patient pools. And the third thing is where we feel like we have a right to win.

We've got strong commercial presence, a good reputation. We understand the clinical nature of it. We understand the technologies, et cetera. And that's where our capital allocation is focused. We've much more prioritized in these high growth areas, much more of
a top-down at the at our leadership team level, allocating that capital. And you're seeing the uptick in MA already, okay? That's broad base, organic and inorganic.

And on the MA, you've seen over the last 18 months, we've been working on this for probably three years, to get that pipeline of MA going. And
it is, it's not the scale deals, it's the tuck-in deals. And it's not just venture, an uptick in venture investing, an uptick in structured deals, ?you know, where you make an investment and then you have strategic optionality later, and then just flat out acquisitions.

You're seeing it across the board, prioritizing those high growth areas. And uh you're getting we announced two more investments today. So you're gonna see that continue uh in in those areas of cardiology, neuroscience, and
and our medical surgical area.

Passages & reports (16)
  • thanks Anthony for the question. I mean I I Terry can comment on the on the uh financial i…
  • you know
  • at the Medtronic level it it it's about 20 basis points, right? It's not,
  • you
  • know, and with our growth accelerating, uh, you know, we're very comfortable. And as we kn…
  • You know,
  • look, the the diabetes business is it is fundamentally different from the rest of Medtroni…
  • getting that capital allocation question,
  • you
  • know, I wouldn't say anything's changed. We've already made that switch, and you're seeing…
  • the third thing is where we feel like we have a right to win. We've got strong commercial …
  • a top-down at the at our leadership team level, allocating that capital. And you're seeing…
  • it is, it's not the scale deals, it's the tuck-in deals. And it's not just venture, an upt…
  • you
  • know, where you make an investment and then you have strategic optionality later, and then…
  • and our medical surgical area.

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 2

don't know what to add, Jeff. Jeff, that was a pretty complete answer. Just a couple numbers. I mean, ?you know, Jeff said it's about 20 basis points of growth. It is lower margin. So when we deconsolidate diabetes, our gross margin will go up about 50 basis points. Our operating margin will go up about 100 basis points. You know, it it typically the RD as a percentage of revenue is about double in diabetes what the rest of the business is.

So it does give us an opportunity to reallocate capital to the other segments of the company where we typically get better returns. As Jeff said, this is not a going forward when we deconsolidate. It's something that we've already started doing. So if you look at
the last 12 months or so, we went from doing about 2.8 billion of RD and half a billion of acquisitions to almost three in RD and 2 billion acquisitions in so or investments.

So we we more than doubled the investment in innovation. And that's something that we intend to continue doing
going forward. So that's the recipe. And and again, diabetes the separation gives us some flexibility to do more of that. From a buyback perspective, you know, no specific plans in that area, but you know, never never close to if the conditions are right, doing it for tactical reasons.

Passages & reports (6)
  • don't know what to add, Jeff. Jeff, that was a pretty complete answer. Just a couple numbe…
  • you know,
  • Jeff said it's about 20 basis points of growth. It is lower margin. So when we deconsolida…
  • what the rest of the business is. So it does give us an opportunity to reallocate capital …
  • the last 12 months or so, we went from doing about 2.8 billion of RD and half a billion of…
  • going forward. So that's the recipe. And and again, diabetes the separation gives us some …

Speaker 1

And just to kind of further emphasize the point and get into our mindset, just go back and look at some of our actions, right? In terms of prioritizing these high growth areas. We had a take CAS, right, which we just talked about, AFib ablation. We had an organic we have an organic program, Paul Select. And at the same time we thought the space was so important, we decided to go out and invest a billion dollars in an inorganic platform.

So multiple shots on goal, and here we are today uh announcing these type of results, we picked up another nine points a share in the highest
growth, you know, one of the highest growth segments in Medtech. I ?mean, we want to put together these these uh decisive winning strategies. And then we talked about soft tissue surgery, you know, soft tissue surgery. Again, a lot of investments organically in Hugo and and and and that ecosystem around it, like the digital platform uh with touch surgery.

And then here we go today announcing
uh an inorganic investment, again, doubling down on these high growth spaces where we believe we have a right to win and putting together winning strategies.

Passages & reports (6)
  • And just to kind of further emphasize the point and get into our mindset, just go back and…
  • Paul Select. And at the same time we thought the space was so important, we decided to go …
  • growth, you know, one of the highest growth segments in Medtech. I
  • mean,
  • we want to put together these these uh decisive winning strategies. And then we talked abo…
  • uh an inorganic investment, again, doubling down on these high growth spaces where we beli…

Speaker 2

Hey, just one thing I I want to add, uh, because it's important. Um you know, you might have seen in the numbers this morning, our free cash flow performance for the first quarter was very strong. ?Uh cash conversion is is improving. Uh you know, we were at 70% in the first quarter, which is good, ?but we think we have a strong path for getting to 80%.

We've got a strong balance sheet. So independently of the diabetes uh deal, we've we've got a lot of firepower to go do this investment. So we look forward to continuing to deploy capital.

Passages & reports (5)
  • Hey, just one thing I I want to add, uh, because it's important. Um you know, you might ha…
  • Uh
  • cash conversion is is improving. Uh you know, we were at 70% in the first quarter, which i…
  • but
  • we think we have a strong path for getting to 80%. We've got a strong balance sheet. So in…

Speaker 7

Thank you. Excellent core.

Passages & reports (1)
  • Thank you. Excellent core.

Speaker 2

Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

Okay, great. Matt O'Brien at Piper Sandler, you are up next. Go ahead, Matt.

Passages & reports (1)
  • Okay, great. Matt O'Brien at Piper Sandler, you are up next. Go ahead, Matt.

Speaker unclear

?Great. Thanks. Can you hear me okay?

Passages & reports (1)
  • Great. Thanks. Can you hear me okay?

Speaker 1

Yep.

Passages & reports (1)
  • Yep.

Speaker unclear

?Okay,

Passages & reports (1)
  • Okay,

Speaker 5

so just real

Passages & reports (1)
  • so just real

Speaker 6

quick, ?I know we're

Passages & reports (3)
  • quick,
  • I know
  • we're

Speaker 5

running long. Um, on uh renal

Passages & reports (1)
  • running long. Um, on uh renal

Speaker 4

denervation, I just want to be sure I'm clear on the message here. Um, because obviously

Passages & reports (1)
  • denervation, I just want to be sure I'm clear on the message here. Um, because obviously

Speaker 5

CAS is doing really well. So, how are you thinking about the trajectory of

Passages & reports (1)
  • CAS is doing really well. So, how are you thinking about the trajectory of

Speaker 4

that business

Passages & reports (1)
  • that business

Speaker 5

now, the market opportunity? Any updates on what you're thinking in terms of the market? And then do you really need transradial to um accelerate that that franchise over the next several years? Is it a reimbursement thing? You know, what's really the clear message on real denervation here as we uh um ?uh we get this update here in Q1. Thanks so much.

Passages & reports (3)
  • now, the market opportunity? Any updates on what you're thinking in terms of the market? A…
  • uh
  • we get this update here in Q1. Thanks so much.

Speaker unclear

?Well,

Passages & reports (1)
  • Well,

Speaker 1

thanks for the question, Matt, on on RD and I still um we have a confidence and conviction that this is gonna be one of the biggest things in med tech, right? It it and there's three things driving it. You touched on some of them. You know, one is the improving clinical evidence, which I'll touch upon. The other is broader reimbursement coverage, and the third is is market development.

In terms of the evidence, right? Um the real world outcomes just keep getting better. I don't know what else to say. We had great three year data at CRT where you saw like a 18, over 18-point reduction
in the office, uh over a 13-point uh reduction in the ambulatory setting. I mean, this is these are materially higher, like two, three X, four X higher than the clinical trial. ?

And
then we put in the commentary today, spiral affirm was accepted as a late breaker TCT. So more data coming out, it's uh I think that's full six month data coming out in a in a very visible conference. So you're what you're seeing is the difference from the trial is material in terms of the improved uh results. Uh, and we're also seeing really strong durability of these results, uh, especially versus like ultrasound.

So this is driving uh the conversation is shifting, right? The KOLs are and and hospitals are are are coming to us to really get some of these programs going as they see this continued
uh improvement uh in in clinical evidence. Also driving that would be more improvement in reimbursement coverage, right? Beyond the national coverage decision for CMS, we're seeing these commercial payers continue to jump on board.

And this quarter we had a number of them, you know, particularly we had some bigger ones like high mark.

Passages & reports (7)
  • thanks for the question, Matt, on on RD and I still um we have a confidence and conviction…
  • I'll touch upon. The other is broader reimbursement coverage, and the third is is market d…
  • in the office, uh over a 13-point uh reduction in the ambulatory setting. I mean, this is …
  • And
  • then we put in the commentary today, spiral affirm was accepted as a late breaker TCT. So …
  • the improved uh results. Uh, and we're also seeing really strong durability of these resul…
  • uh improvement uh in in clinical evidence. Also driving that would be more improvement in …

So we're seeing that reimbursement coverage uh improve. ?And then the market development, that's where a lot of the focus is now. And look, as you you I know, Matt, you get out there, you talk to a lot of the KOLs, and uh you know, we're out there talking to them as well as the the hospital C-suite. Uh and the conversation, like I said, is shifting.

Uh the enthusiasm's there, and we're really partnering with them to build out these programs on the back of the clinical evidence, on the back of more insurance coverage, building out those referral uh pathways and driving consumerslash patient awareness on these. So again, you know,
we thought we made a good progress on a number of those leading indicators, and it bodes well for the ramp here over the next you know quarters and and years to

Passages & reports (5)
  • So we're seeing that reimbursement coverage uh improve.
  • And
  • then the market development, that's where a lot of the focus is now. And look, as you you …
  • I said, is shifting. Uh the enthusiasm's there, and we're really partnering with them to b…
  • we thought we made a good progress on a number of those leading indicators, and it bodes w…

Speaker unclear

?come.

Passages & reports (1)
  • come.

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 0

right, I think we have time for two more. So the next question comes from Robbie Marcus at JP Morgan.

Passages & reports (1)
  • right, I think we have time for two more. So the next question comes from Robbie Marcus at…

Speaker unclear

?Oh, great. Uh

Passages & reports (1)
  • Oh, great. Uh

Speaker 6

congrats

Passages & reports (1)
  • congrats

Speaker unclear

?on the

Passages & reports (1)
  • on the

Speaker 4

nice quarter. Um Terry wanted to ask on margins. Um this quarter it came in just a bit above the street on operating margin. How are you thinking about reinvesting this top line upside versus driving margin expansion, both in the first quarter and for the rest of the year. And then uh quick follow up. You talked about tariffs, rebates, offsetting, tariffs paid. Um do you have the uh tariff rebate number so we can all keep track of that as uh some some of the uh the one time benefits in the quarter?

Thanks a lot.

Passages & reports (3)
  • nice quarter. Um Terry wanted to ask on margins. Um this quarter it came in just a bit abo…
  • both in the first quarter and for the rest of the year. And then uh quick follow up. You t…
  • the quarter? Thanks a lot.

Speaker 2

Yeah, thanks, Rabi. So I'll start with uh with the rebates uh with the tariffs. Sorry. So uh the refunds in in the first quarter were such that we were nights uh slight net negative on the impact from tariffs. So they almost compensated the full tariffs. Going forward for the year, just to be clear, we have not embedded future refunds. So, you know, wanted to remain prudent going forward.

So we're we have a construction for the remainder of the year that that doesn't bank on any any refunds happening. We are continuing to submit to submit for refunds. So there's a potential uh potential upside
coming from ?that. Uh from a margin uh expansion perspective, look, you know, we're in growth mode, so we're taking a portion of the upside that we're seeing from a revenue perspective and reinvesting in in the growth areas, and a portion only.

And so the construction that we've got on a four year basis today still calls for
uh an operating margin ?uh that should be up about 50 basis points on a four year basis, uh, which uh should put us with a not profit uh up uh up 10%, so significantly higher than our our revenue growth. So look, we're we're going through you know all the different parts of the company, right?

Cost of goods
sold, the manufacturing efficiency, uh the relationships with the suppliers. We're looking at logistics cost and we're looking at overhead, and we're really looking at how we can drive efficiency at every level. And it's it's starting to pay off. You've seen some of it in the first quarter, and on the four-year, we're we're gonna deliver a a leverage PL.

Passages & reports (10)
  • Yeah, thanks, Rabi. So I'll start with uh with the rebates uh with the tariffs. Sorry. So …
  • clear, we have not embedded future refunds. So, you know, wanted to remain prudent going f…
  • coming from
  • that. Uh
  • from a margin uh expansion perspective, look, you know, we're in growth mode, so we're tak…
  • uh an operating margin
  • uh
  • that should be up about 50 basis points on a four year basis, uh, which uh should put us w…
  • sold, the manufacturing efficiency, uh the relationships with the suppliers. We're looking…
  • gonna deliver a a leverage PL.

Speaker unclear

?Appreciate it. Thanks a

Passages & reports (1)
  • Appreciate it. Thanks a

Speaker 0

All right. ?I'm waiting for my cue up here on our last question. ?It should come from perfect. Rick wise at Stefan. All right, thanks. Rick, please go ahead.

Passages & reports (5)
  • All right.
  • I'm
  • waiting for my cue up here on our last question.
  • It
  • should come from perfect. Rick wise at Stefan. All right, thanks. Rick, please go ahead.

Speaker 1

Rick, you there?

Passages & reports (1)
  • Rick, you there?

Speaker unclear

?It

Passages & reports (1)
  • It

Speaker 2

might be on mute, Rick.

Passages & reports (1)
  • might be on mute, Rick.

Speaker unclear

?You

Passages & reports (1)
  • You

Speaker 1

want to go to the next one?

Passages & reports (1)
  • want to go to the next one?

Speaker 0

Yeah. ?All right, Rick, we'll we'll get you on the on the next one, please. Um the next question is going to come from Joanne then. Joanne at City.

Passages & reports (3)
  • Yeah.
  • All
  • right, Rick, we'll we'll get you on the on the next one, please. Um the next question is g…

Speaker unclear

?Uh good

Passages & reports (1)
  • Uh good

Speaker 4

morning. Thank you so much for taking the question and really nice quarter. ?Um to wrap it up, I think I'll ask about Charlotte, uh North Carolina, and why are we going there and what can we expect from the analyst ?meeting? And my second question sort of probably

Passages & reports (5)
  • morning. Thank you so much for taking the question and really nice quarter.
  • Um
  • to wrap it up, I think I'll ask about Charlotte, uh North Carolina, and why are we going t…
  • meeting?
  • And my second question sort of probably

Speaker unclear

?ties to that one. Um,

Passages & reports (1)
  • ties to that one. Um,

Speaker 4

for ?a while, ?um I used to think of Medronic, or we used to think of Medronic as sort of a mid single digit revenue grower, ?high single

Passages & reports (7)
  • for
  • a
  • while,
  • um
  • I used to think of Medronic, or we used to think of Medronic as sort of a mid single digit…
  • high
  • single

Speaker unclear

?digit EPS. Has that formula shifted? Thank you. Well,

Passages & reports (1)
  • digit EPS. Has that formula shifted? Thank you. Well,

Speaker 1

look, I'll I'll ?uh I'll I'll start with your last questi the the back half of the question and let Terry pile on there. Uh but look, we're Terry mentioned between, you know, um the strong cash flow that we're generating, where you know, our cash flow is uh improving here, continues to improve. It's always been good, but it's improving, had a really strong quarter, and we're going to continue focus on that.

And then our focus on uh gross margin and operating margins uh are gonna allow us to invest more, both organically and inorganically. Uh and in ramping up our inorganic uh tuck-in acquisitions, combining that with our organic, you know,
you're seeing effectively a doubling of our investment and innovation. And we've been doing this for a while, and now you're seeing that growth tick ?up.

And uh clearly we um have aspirations for higher growth than we've done historically. You've seen over the last couple of years we've you know gotten the growth to mid-single digits, but we're not satisfied with that. That's why the more investments and the focus on execution. We have I I can't describe in words
the sense of urgency on on the investments and the execution to continue.

You've seen in the last two quarters a bit of an inflection of growth, and and we want to you know kind of stick continue continue with that. Um so before I get to the the uh Charlotte, uh Thierry, any other
comments on that?

Passages & reports (9)
  • look, I'll I'll
  • uh
  • I'll I'll start with your last questi the the back half of the question and let Terry pile…
  • it's improving, had a really strong quarter, and we're going to continue focus on that. An…
  • you're seeing effectively a doubling of our investment and innovation. And we've been doin…
  • up.
  • And uh clearly we um have aspirations for higher growth than we've done historically. You'…
  • the sense of urgency on on the investments and the execution to continue. You've seen in t…
  • comments on that?

Speaker 2

No, look, I I I think you said it all. So we're clearly at an inflection from a growth perspective and and we're working the PL. As I just said, you know, we're continuing to make progress in pricing, we're continuing to make progress in cost out, we're reinvesting in in in innovation, but we're you know, we're getting leverage from an overhead perspective.

Passages & reports (2)
  • No, look, I I I think you said it all. So we're clearly at an inflection from a growth per…
  • you know, we're getting leverage from an overhead perspective.

Speaker 1

Right.

Passages & reports (1)
  • Right.

Speaker 2

Uh so you know, we're really focused on on driving the leverage on the income statement as well. And it's one of the things that we'll talk about in Charlotte.

Passages & reports (1)
  • Uh so you know, we're really focused on on driving the leverage on the income statement as…

Speaker 1

Yep. And so Charlotte, you know, why are we going there? So look, the ERCAD uh facility there in Charlotte is an impressive facility. Um you know, ERCAD we i i i is mainly uh uh historically outside of does physician training outside of the US. This is their first North American site, uh and we're we're we have a big presence in that site.

And it's a good way, Joanne, to actually see, especially a lot of our technology now is, or more and more of it is capital. So you got our Able platform and stealth access. You have all of our soft tissue technology, which we keep
adding to. You have the digital piece. It really helps to see it in action, and ERCAT is set up so that you can actually see it.

We'll have physicians there walking you through it and describing how they're using it. And these are physicians that also use our competition. We all have our weak
moments, but they'll be able to provide, you know, I think a good balance of how we stand up versus the competition. And we'll talk about where we're going with these technologies as well. And then the other thing, look, on these earnings calls and some of our other events that we do, the different uh, you know, banking meetings, we don't get a chance to go in depth uh with some of the other parts of our growth pipeline.

And so there's a lot that we haven't talked about that we're going to talk about. And in addition to that, you're going to go down a layer into the
org below my leadership team to some of the business unit leaders and the experts in these specific areas, and you're going to hear it from them as well. So physicians plus the business unit leaders themselves, new growth uh new growth investments that we haven't talked about, and then going way deeper into some of these big areas, like these surgical ecosystems.

Uh and in a in a in a um a showcase uh a space that is built for this.

Passages & reports (7)
  • Yep. And so Charlotte, you know, why are we going there? So look, the ERCAD uh facility th…
  • we're we're we have a big presence in that site. And it's a good way, Joanne, to actually …
  • adding to. You have the digital piece. It really helps to see it in action, and ERCAT is s…
  • moments, but they'll be able to provide, you know, I think a good balance of how we stand …
  • uh, you know, banking meetings, we don't get a chance to go in depth uh with some of the o…
  • org below my leadership team to some of the business unit leaders and the experts in these…
  • of these big areas, like these surgical ecosystems. Uh and in a in a in a um a showcase uh…

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 1

so December 10th and 11th, please mark your your your calendar. Um it's it's uh we're we're really excited to share uh and I know the team is as well. ?So thanks for the question, Joanne.

Passages & reports (3)
  • so December 10th and 11th, please mark your your your calendar. Um it's it's uh we're we'r…
  • So
  • thanks for the question, Joanne.

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 0

right, great. ?Well that wraps up the call. So thank you everyone very much for joining. I appreciate your support and continued interest in Medtronic. Um ?and uh Jeff, if you have any other additional prepared remarks, please go.

Passages & reports (5)
  • right, great.
  • Well
  • that wraps up the call. So thank you everyone very much for joining. I appreciate your sup…
  • and
  • uh Jeff, if you have any other additional prepared remarks, please go.

Speaker 1

I I mean look, thanks for for thanks as always, Frank's for joining today. Really appreciate the engagement, appreciate the support and uh and the continued interest in in Medtronic. Uh with that, you know, have a great rest of your day and and thank you very much.

Passages & reports (1)
  • I I mean look, thanks for for thanks as always, Frank's for joining today. Really apprecia…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

2 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 2. Unassigned words: 213. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T01:56:35.366Z.
Transcript version v1-4e020735eaee7838f7d0 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.